188宝金博页面版

Zou et al. Cardiovasc Diabetol (2018) 17:38 https://doi.org/10.1186/s12933-018-0676-1CORRECTIONCorrection to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney diseaseHonghong Zou † , Baoqin Zhou † and Gaosi Xu *© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Correction to: Cardiovasc Diabetol (2017) 16:65 https://doi.org/10.1186/s12933-017-0547-1Following publication of the original article [1] the authors reported that the fi rst af f i liation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the correct author information is as given in this erratum.Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in pub-lished maps and institutional af f i liations.Received: 19 February 2018 Accepted: 19 February 2018Reference 1. Zou H, Zhou B, Gaosi X. SGLT2 inhibitors: a novel choice for the combina-tion therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16:65. https://doi.org/10.1186/s12933-017-0547-1.Open AccessCardiovascular Diabetology*Correspondence: gaosixu@163.com † Honghong Zou and Baoqin Zhou contributed equally to this workDepartment of Nephrology, The Second Af f i liated Hospital of Nanchang University, No. 1, Minde Road, Donghu District, Nanchang Zip Code: 330006, People’s Republic of ChinaThe original article can be found online at https://doi.org/10.1186/s12933-017-0547-1.